Since 2012, various types of radiodiagnostics or radiotherapeutics have appeared on the market and have shown great potential. The radiodiagnostics FDG is currently covered by many health insurance benefit packages, and the need for development of novel radioligand theranostics is urgent.
The professional and dedicated Primo team has been engaged in extensive clinical trials of new drugs for TFDA (Taiwan Food and Drug Administration) and CDE (Center for Drug Evaluation) as well as drug development experiences for radiopharmaceuticals. We are here to protect your health so that we may all enjoy a better tomorrow.